Will MDMA-assisted psychotherapy become a breakthrough in treatment-resistant post-traumatic stress disorder? A critical narrative review.
More details
Hide details
Studenckie Koło Naukowe przy Katedrze i Oddziale Klinicznym Psychiatrii, Wydział Nauk Medycznych w Zabrzu, Śląski Uniwersytet Medyczny w Katowicach
Katedra i Oddział Kliniczny Psychiatrii, Wydział Nauk Medycznych w Zabrzu, Śląski Uniwersytet Medyczny w Katowicach
Submission date: 2020-10-16
Final revision date: 2021-03-03
Acceptance date: 2021-03-03
Online publication date: 2022-08-31
Publication date: 2022-08-31
Corresponding author
Gniewko Więckiewicz   

Katedra i Oddział Kliniczny Psychiatrii w Tarnowskich Górach, Śląski Uniwersytet Medyczny w Katowicach
Psychiatr Pol 2022;56(4):823-836
Post-traumatic stress disorder (PTSD) is a common mental health condition that begins after exposure to a traumatic event. Despite recommended various therapeutic approaches, including both pharmacotherapy and psychotherapy, treatment is not as effective as expected. Over recent years the pharmaceutical industry has not been able to offer a new approach, founded on multiple mechanisms of action. That is why a part of researchers focused on psychoactive substances synthesized years ago and then banned. These days MDMA-assisted psychotherapy for the treatment of PTSD clinical trials are conducted, and due to previous results, the Food and Drug Administration (FDA) granted a breakthrough therapy designation. In this article, we present the mechanism of actions, the therapeutic rationale, applied psychotherapeutic methods, and potential dangers. If ongoing phase 3 studies are completed and clinical efficacy criteria are achieved, the FDA could approve the treatment as early as 2022.
Journals System - logo
Scroll to top